BioLife shareholders should vote FOR the merger proposal at the special meeting on October 5, 2026. If approved, the merger is expected to close in Q4 2026, and shares should trade near the implied merger consideration value until closing. Monitor for any competing proposals or regulatory delays.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Sep 8 $35.38entry
- T+1 · 2mo ago −1.27%α −0.81% · $34.93
- T+5 · 2mo ago +2.85%α +3.97% · $36.39
- T+20 · 6w ago +9.13%α +7.42% · $38.61
- T+49 · todayOpen
- T+60 · in 15d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BioLife Solutions (BLFS) is seeking stockholder approval for its acquisition by Repligen Corporation (RGEN) in a cash-and-stock deal offering $11.25 cash plus 0.1442 RGEN shares per BLFS share. The BioLife board unanimously recommends voting FOR, with the special meeting scheduled for October 5, 2026. If approved, the merger is expected to close in Q4 2026, and BLFS stockholders will own approximately 11.1% of the combined company.
Key Financial Metrics
Key Facts
- Merger consideration: $11.25 cash + 0.1442 shares of Repligen common stock per BioLife share
- Implied value per BioLife share: $31.00 as of July 21, 2026 (pre-announcement) and $36.19 as of September 2, 2026
- BioLife stockholders will own approximately 11.1% of Repligen post-merger
- Special meeting: October 5, 2026; vote requires majority of outstanding shares
- Board unanimously recommends FOR (with Tony Hunt recused)
- Centerview Partners fairness opinion: consideration fair from a financial point of view
- Termination fee of $59 million payable by BioLife in certain circumstances
- Appraisal rights available under Delaware law
- Expected closing: Q4 2026, subject to stockholder approval, HSR clearance, and other conditions
Financial Impact
Per share consideration of $11.25 cash plus 0.1442 shares of Repligen common stock, implying a value of approximately $36.19 per BioLife share as of September 2, 2026.
Risk Factors
- Failure to obtain stockholder approval (requires majority of outstanding shares)
- Regulatory hurdles including HSR and foreign investment approvals
- Termination fee of $59 million if deal falls through under certain conditions
- Potential for appraisal rights litigation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFM14A Filing (Primary) | 0001193125-26-383837 |
| Document: d112843ddefm14a.htm | 0001193125-26-383837 |
Track record
15 reports on BLFS
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry price pending
- Nov 6, 202610d ago Institutional Cluster Bearish 4/10 No price data
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 No price data
- Oct 16, 20264w ago 15-12G Neutral 4/10 No price data
- Oct 13, 20264w ago EFFECT Neutral 3/10 No price data
- Oct 13, 20264w ago EFFECT Neutral 3/10 No price data
- Oct 6, 20265w ago 8-K Bullish 7/10 Entry $39.00 No price data
- Sep 30, 20266w ago 425 Neutral 4/10 Entry $38.85 No price data
- Sep 30, 20266w ago DEFA14A Neutral 4/10 Entry $38.85 No price data
- Sep 24, 20267w ago SC 13G Neutral 4/10 Entry $38.58 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers